Alliance Pharma (LON:APH) Wide 2014 Price Channel Points To 45p Plus

Alliance Pharma (LON:APH) is currently sporting a daily chart which inspired technical confidence, if nothing else. This is because over the initial part of 2015 we have been treated to an extended double bounce off the 200 day moving average now at 33.98p. There is also the backing of a wide rising trend channel which can be drawn from the beginning of 2014p, one which has its base effectively at the 200 day line level. All of this goes to suggest that much of the heavy lifting with regard to the shares putting in an extended floor prior to a fresh sustained journey to the upside.

APH Alliance Pharma Technical Analysis 020415

Just how high this could stretch is currently suggested by the resistance line projection of last year which is pointing as high as 45p plus. This is a destination that one would expect to be hit as soon as the next 1-2 months, especially while the 50 day moving average now at 35.33p remains in place as support. Indeed, it can be said that while there is no end of day close back below the 50 day line the stock should start to accelerate to the upside. Only cautious traders would wait on a clearance of early 2015 resistance at 38p before taking the plunge on the long side.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    DirectorsTalk

    More articles like this

    Hardman & Co

    Alliance Pharma International brands driving performance

    Alliance Pharma (LON:APH) is a profitable, cash-generative, specialty pharma business. The proportion of sales generated from higher margin international star brands is rising rapidly, and will be boosted by the recent acquisition of Nizoral in APAC,

    Hardman & Co

    Alliance Pharma Entering the US market

    Alliance Pharma Plc (LON:APH) is continuing with its buy-and-build strategy having evolved through 35 acquisitions over a period of 20 years into a profitable, cash-generative, specialty pharma business. The company has a mix of international growth

    Hardman & Co

    Alliance Pharma Kelo-cote building international sales

    Alliance Pharma Plc (LON:APH) buy-and-build strategy is to evolve into a profitable, cash generative, specialty pharma business is bearing fruit. Acquisition of the dermatology and wound care products from Sinclair Pharma has transformed the company into

    Hardman & Co

    Alliance Pharma Plc A transformational year driving growth

    Alliance Pharma Plc (LON:APH) buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma was transformational, doubling the size of

    Hardman & Co

    Alliance Pharma Plc Potential of Diclectin

    Alliance Pharma plc (LON:APH) buy-and-build strategy which is to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma was transformational, doubling the

    Hardman & Co

    Alliance Pharma Plc Managing a period of change

    Alliance Pharma Plc (LON:APH) has adopted a buy-and-build strategy to evolve through a series of 28 acquisitions into a profitable, cash generative, specialty pharma business. The acquisition of part of the dermatology and wound-care products from